Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2012

View Archived Issues

Isis Innovation presents new dsNA molecules for Parkinson's disease

Del Mar Pharmaceuticals expands collaboration with Guangxi Wuzhou Pharmaceutical

Global phase III trial of ART-123 commences

AstraZeneca begins new global study of Faslodex

Astex Pharmaceuticals, CRT and Newcastle University form drug discovery alliance

Chinese researchers disclose novel Lp-PLA2 inhibitors

Astellas Pharma prepares new PDE10A inhibitors

New modulators of the expression of aquaporin-3 patented by Lipotec

Dainippon Sumitomo Pharma synthesizes novel nACh alpha7 receptor modulators

Researchers at Pathway Therapeutics disclose new PI3K inhibitors

Complix receives government grant for Alphabodies development

Takeda submits Japanese NDA for cetilistat

Astellas Pharma launches Quattrovac vaccine in Japan

Combination of BKM-120 and irinotecan evaluated in phase I trial

TransTech Pharma's TTP-488 slows cognitive decline in Alzheimer's disease

Preliminary phase II data presented for lubrinectedin in ovarian cancer

Cytokinetics begins phase IIb BENEFIT-ALS trial

Amgen offers overview of third quarter 2012 results

Novartis reports third quarter results for 2012

European Commission approves Cialis in new indication

FDA accepts two Latuda supplemental NDAs for review

Oral salmon calcitonin shows potential as antidiabetic therapy in vivo

GSK begins phase III program for mepolizumab in severe refractory asthma

Phase I IPH-2102 trial begins patient recruitment

NCI presents phase II data for a cervical cancer vaccine

Semaphorin-3A demonstrates osteoprotective qualities and therapeutic potential

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...